The therapeutic potential of Vx765 was illustrated not only by its inhibition of IL‐1β releases from human monocytes in vitro, but also by its effect in reducing the serum levels of IL‐1β and other clinical biomarkers in murine models of dermatitis, arthritis,11 and temporal lobe epilepsy.12 The gene discussed is IL1B; the disease is temporal lobe epilepsy.